Quercetin for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

Quercetin for Health & Longevity

Created on 08/10/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 – Audit

Quercetin modestly lowers blood pressure at about 500 mg daily or more. Secondary signals include fewer COVID hospital stays with better-absorbed forms, tiny endurance gains, and possible cholesterol shifts when overweight. Main risks are gastrointestinal discomfort and drug interactions. Product quality varies. Dasatinib combinations need medical oversight—not a proven lifespan drug. (Full Review)

Protocol

Standard daily supplemental range
500–1,000 mg/day
Aglycone or dihydrate; split twice daily with meals; <500 mg weaker BP signal
Enhanced-bioavailability forms
250–500 mg twice daily
Phytosome or other high-absorption products; higher exposure at lower labels
Senolytic D+Q (medical supervision only)
Dasatinib 100 mg/day + quercetin 1,000 mg/day
On 2–3 consecutive days; intermittent cycles
Time to effect
Blood pressure
Weeks
Primary validated physiologic effect; larger signal if baseline pressure elevated
Allergy symptoms
Days to weeks
Seasonal mast-cell–oriented use; often started before peak pollen season
Endurance capacity
~1–2 weeks
Short courses around training; effect trivial-to-small

Benefits

Contraindications
  • Pregnancy and breastfeeding (insufficient safety data)
  • Known allergy to quercetin or source botanicals (e.g., Sophora japonica)
  • Critical narrow-therapeutic-index CYP3A4/P-gp substrates without clinical monitoring
  • Advanced kidney failure without specialist input (high-dose chronic use)
  • Self-directed dasatinib + quercetin without medical supervision
    •
Key Interactions
  • CYP3A4 substrates (moderate caution; e.g., felodipine, nifedipine, simvastatin, atorvastatin, midazolam)
  • P-gp substrates (moderate caution; digoxin, some immunosuppressants, fexofenadine)
  • Immunosuppressants (caution / specialist oversight; cyclosporine)
  • Warfarin and other anticoagulants (moderate caution)
  • Antihypertensives (monitor, often additive; ACE inhibitors, ARBs, beta-blockers, diuretics)
  • Antidiabetic agents (monitor; insulin, sulfonylureas)
  • Quinolone antibiotics (theoretical)
  • Other flavonoid / polyphenol stacks (caution; curcumin, EGCG, resveratrol)
  • Senolytic combination partners (Dasatinib)
  • Additive BP- or mast-cell–related supplements (magnesium, potassium, L-arginine, high-dose fish oil, stinging nettle, DAO)
    •

Risk & Side Effects

  • High:
  • Medium: Drug interactions via CYP3A4, P-gp, and related transporters; Gastrointestinal discomfort at high doses
    •
  • Low: Theoretical kidney stress with very high prolonged doses; Estrogenic / hormone-signaling activity in experimental systems; Product quality failures
    •
  • Speculative: Unknown long-term effects of intermittent senolytic high-dose regimens in healthy adults; Pro-oxidant effects under unusual redox conditions
    •

Monitoring

Marker Target Why
Home blood pressure Generally <120/80 mm Hg if pursuing optimization; individual targets vary Primary validated physiologic effect of quercetin
hs-CRP Often <1.0 mg/L as a functional inflammation goal Tracks systemic inflammation that quercetin may modestly influence
Fasting lipid panel (LDL-C, HDL-C, TG) LDL optimized per personal risk; TG often <100–150 mg/dL functionally Detects rare lipid shifts at higher cumulative doses
Fasting glucose / HbA1c Fasting glucose often ~70–90 mg/dL functional; HbA1c individualized Context for metabolic stacking and antidiabetic co-use
eGFR / serum creatinine eGFR in age-appropriate normal; watch trajectory Precaution in high-dose or kidney-disease contexts
ALT / AST Within lab normal; investigate rising trends General safety with polypharmacy
INR (if on warfarin) Per anticoagulation clinic target Interaction risk
CBC (senolytic / dasatinib contexts) Protocol-specific Dasatinib myelosuppression risk

Cadence: Recheck BP within 1–2 weeks of dose changes; labs at ~8–12 weeks for continuous daily use, then every 6–12 months if stable; earlier INR after start/stop if on anticoagulants; senolytic cycles follow clinician-defined safety labs

Qualitative Assessment

  • Seasonal allergy symptom scores (sneezing, congestion, itchy eyes)
  • Perceived recovery and training tolerance
  • GI comfort on the chosen dose and form
  • Energy and exercise capacity (expect subtle changes only)
  • Medication side-effect changes after co-initiation (possible interaction clue)
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.